Instant International
Written by: Hong Yilin
2021-01-18 02:54
Last update date: 2021-01-18 03:20
Brazil's National Health Supervision Agency (Andvisa) approved the new coronavirus pneumonia (COVID-19) vaccine developed by China Kexing Biotechnology on January 17, and the joint research and development of AstraZeneca (AstraZeneca) and Oxford University (Oxford University) New coronary pneumonia vaccine.
After nearly 5 hours of deliberation, the Board of Directors of the National Health Supervision Bureau unanimously voted to approve the above two vaccines.
The Brazilian government plans to launch a national vaccination plan this week, but the vaccine site is still waiting for AstraZeneca to send the vaccine.
The governor of Sao Paulo, Joao Doria, said that it may start to vaccinate people immediately.
New Coronary Pneumonia | Brazil refuses to approve Russia's emergency use of vaccine because it has not submitted enough information
The Brazilian President said it was correct to question the Coxing vaccine: now they see the truth
The effective rate of Kexing vaccine is only 50% far lower than expected.
New crown pneumonia | Brazil said that the effective rate of Kexing vaccine is only over 50%, and it is decided on Sunday whether to use
Doria tweeted before the vote of the Board of Directors of the National Health Inspection Agency that he determined that once the National Health Inspection Agency approved the emergency use of the Butantan vaccine, the Institute would immediately deliver the vaccine to the Ministry of Health and distribute it to States.
The Biomedical Center of the Butantin Institute is a partner of China Kexing Biotechnology in Brazil.
01News
New crown pneumonia new crown vaccine Brazil